BioCentury
ARTICLE | Company News

Mereo, OncoMed announce merger

December 14, 2018 9:02 PM UTC

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ.

The new company's pipeline will include BPS804, a human mAb against sclerostin, in Phase IIb testing for osteogenesis imperfecta; and MPH-966, a neutrophil elastase (ELANE; NE; HLE) inhibitor is in Phase II testing for α-antitrypsin (AAT) deficiency with top-line data slated for 2H19. ...